Advancing the treatment of people with mental illness: A call to action in the management of metabolic issues

Journal of Clinical Psychiatry

Volumn 66, Issue 6, 2005, Pages 790-798

  Franciosi, L Patt ^a   Kasper, Siegfried ^b  

^a World Federation for Mental Health   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; PSYCHOTROPIC AGENT;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY WEIGHT; BODY WEIGHT DISORDER; CLINICAL RESEARCH; DIABETES CONTROL; DIABETES MELLITUS; DIET THERAPY; DRUG CHOICE; DRUG SUBSTITUTION; EXERCISE; FAMILY; GENERAL PRACTITIONER; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFORMED CONSENT; LIFESTYLE; LIPID BLOOD LEVEL; MEDICAL EDUCATION; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC SYNDROME X; PARKINSONISM; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; RISK FACTOR; RISK REDUCTION; SEDATION; SIDE EFFECT; WEIGHT GAIN;

EID: 21744437277     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v66n0619     Document Type: Review

References (70)

1. Ninomiya JK, L'Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004;109:42-46
2. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110: 1245-1250
3. Kereiakes DJ, Willerson JT. Metabolic syndrome epidemic. Circulation 2003; 108:1552-1553
4. Scheen AJ, Luyckx FH. Metabolic syndrome: definitions and epidemiological data [in French]. Rev Med Liege 2003; 58:479-484
5. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004;27: 2444-2449
6. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003;163:427-436
7. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003;108:1541-1545
8. Gupta R, Deedwania PC, Gupta A, et al. Prevalence of metabolic syndrome in an Indian urban population. Int J Cardiol 2004;97:257-261
9. Ramachandran A, Snehalatha C, Satyavani K, et al. Metabolic syndrome in urban Asian Indian adults: a population study using modified ATP III criteria. Diabetes Res Clin Pract 2003;60:199-204
10. Azizi F, Salehi P, Etemadi A, et al. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract 2003;61: 29-37
11. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am Heart J 2004;147:106-112
12. Bonora E, Kiechl S, Willeit J, et al. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord 2003;27: 1283-1289
13. Park HS, Oh SW, Cho SI, et al. The metabolic syndrome and associated lifestyle factors among South Korean adults. Int J Epidemiol 2004;33:328-336
14. Holt RI, Peveler RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 2004;21:515-523
15. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002;71: 239-257
16. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl 2004;47:S76-S79
17. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004; 65(suppl 7):4-18
18. Alméras N, Després J-P, Villeneuve J, et al. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 2004;65:557-564
19. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psychiatry 2004;65:267-272
20. Newcomer JW. Atypical antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(suppl 1):1-93
21. Siris SG. Suicide and schizophrenia. J Psychopharmacol 2001;15:127-135
22. Meyer JM. Treating the mind and body in schizophrenia: risks and prevention. CNS Spectr 2004;9(10 suppl 11):25-33
23. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58:844-850
24. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161: 1334-1349
25. Dinan TG. Schizophrenia and diabetes 2003: expert consensus meeting. Br J Psychiatry Suppl 2004;47:S53-S54
26. Lambert TJ, Chapman LH, on behalf of the Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181:544-548
27. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 2004;109: 433-438
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285: 2486-2497
29. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Geneva, WHO; 1999
30. Balkau B, Charles MA, Drivsholm T, et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364-376
31. Isomaa B. A major health hazard: the metabolic syndrome. Life Sci 2003; 73:2395-2411
32. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without c-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-419
33. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 2003;107:391-397
34. Olijhoek JK, van der Graaf Y, Banga JD, et al. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004;25:342-348
35. Grundy SM, Hansen B, Smith SC Jr, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on scientific issues related to management. Circulation 2004;109:551-556
36. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-1610
37. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-220
38. Thakore JH, Mann JN, Vlahos I, et al. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002;26:137-141
39. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-217
40. Bushe C, Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl 2004;47:S67-S71
41. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856-865
42. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70:1-17
43. McCreadie RG, on behalf of the Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003;183:534-539
44. Kumar CT. Physical illness and schizophrenia [letter]. Br J Psychiatry 2004; 184:541
45. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696
46. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of antipsychotic induced weight gain on health and mortality rate. Psychiatry Res 2001;101:277-288
47. Toalson P, Ahmed S, Hardy T, et al. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry 2004;6:152-158
48. Kasper S, Hale A, Azorin JM, et al. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci 1999;249(suppl 2):II1-II14
49. Clozaril [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2002
50. Procyshyn RM, Chau A, Tse G. Clozapine's effects on body weight and resting metabolic rate: a case series. Schizophr Res 2004;66:159-162
51. Newcomer JW, Nasrallah HA, Loebel AD. The atypical antipsychotic therapy and metabolic issues national survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004;24 (5 suppl 1):S1-S6
52. Wylie G, Hungin AP, Neely J. Impaired glucose tolerance: qualitative and quantitative study of general practitioners' knowledge and perceptions. BMJ 2002;324:1190
53. Boilson M, Hamilton RJ. A survey of monitoring of weight and blood glucose in in-patients. Psychiatr Bull 2003;27: 424-426
54. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004;24(5 suppl 1): S7-S14
55. Groom G, Hickie I, Davenport T. Out of hospital, out of mind: a report detailing mental health services in Australia in 2002 and community priorities for national mental health policy for 2003-2008. Canberra, Australia: Mental Health Council of Australia; 2003:1-80
56. Koran LM, Sox HC Jr, Marton KI, et al. Medical evaluation of psychiatric patients, 1: results in a state mental health system. Arch Gen Psychiatry 1989;46:733-740
57. Phelan M, Stradins L, Morrison S. Physical health of people with severe mental illness [editorial]. BMJ 2001;322:443-444
58. Van Os J, Altamura AC, Bobes J, et al. Evaluation of the two-way communication checklist as a clinical intervention: results of a multinational, randomised controlled trial. Br J Psychiatry 2004;184:79-83
59. DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol 2004;23:207-218
60. Laville M. Is it possible to prevent type 2 diabetes? [in French] Ann Endocrinol (Paris) 2003;64:S37-44
61. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346: 393-403
62. Druss BG, Rohrbaugh RM, Levinson CM, et al. Integrated medical care for patients with serious psychiatric illness: a randomized trial. Arch Gen Psychiatry 2001;58: 861-868
63. Kates N, Craven M, Bishop J, et al. Shared mental health care in Canada. Can J Psychiatry 1997;42 (suppl 12 pp)
64. Department of Health and Human Services (DHHS). Report of a Surgeon General's working meeting on the integration of mental health services and primary health care. Nov 30-Dec 1, 2000; Atlanta, Ga. Rockville, Md: US DHHS, Public Health Service, Office of the Surgeon General; 2001
65. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 2004;79:379-384
66. Carroll S, Dudfield M. What is the relationship between exercise and metabolic abnormalities? a review of the metabolic syndrome. Sports Med 2004;34:371-48
67. Hill JO, Wyatt H. Outpatient management of obesity: a primary care perspective. Obes Res 2002;10(suppl 2):124S-130S
68. Littrell KH, Hilligoss NM, Kirshner CD, et al. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 2003;35:237-241
69. Steinberg ML, Ziedonis DM, Krejci JA, et al. Motivational interviewing with personalized feedback: a brief intervention for motivating smokers with schizophrenia to seek treatment for tobacco dependence. J Consult Clin Psychol 2004;72:723-728
70. Ruggeri M, Lasalvia A, Bisoffi G, et al. Satisfaction with mental health services among people with schizophrenia in five European sites: results from the EPSILON study. Schizophr Bull 2003;29:229-245